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Ion channels are pore-forming proteins and their 
function is to facilitate the diffusion of ion across cell 
membranes by flow of ions down the electrochemical 
gradient. Voltage-gated ion channels are a class of 
transmembrane ion channels and are found throughout 
the body which allowed a rapid and coordinated 
depolarization in response to voltage change in 
excitable cells (Catterall, 2010). Recent studies have 
demonstrated that Voltage-gated ion channels had been
found in non-excitable cells. Among these channels, 
Voltage-gated sodium channels (VGSC) are the new 
topic and increasing evidences have suggested that 
which participated in the oncogenic process (Fiske et 
al., 2006; Mechaly et al., 2005). 
1. VGSC subunits and structure 
VGSC is a large transmembrane glycoprotein 
complexes, composed of a highly processed α subunits 
(VGSCαs) with 24 transmembrane domains and one or 
more regulatory β subunits (VGSCβs), which mediate 
the all-or-none action potential initiation and 
propagation in excitable cells and tissues. When VGSC 
is activated, influx of sodium ions through channel 
depolarizes the cell membrane and initiates the rising 
phase of the action potential (Catterall, 2000). 
VGSCαs are approximately 260 kDa, which have been 
identified ten encoding genes up to now. According to 
the phylogeny difference, Nav1.1 to Nav1.9 of nine 
isoforms constitute the functional subunits of VGSCαs 
and name Nav1 family, there are greater than 50% 
identical in amino acid sequence in these structure. As 
for another isoform Nax, its structure and function are 
different with Nav1 family and which seem to be 
regulated by sodium concentration but not by voltage. 
In case of Nav1 family, each isform is made up of a 
single polypeptide with 4 homologous domains (D1-
D4) and every domain has 6 transmembrane segments 
(S1-S6). There are several functional parts about Nav1 
structure. Among them, the S4 serves as a voltage 
sensor, which responds to the levels of the membrane 
potential, the S5/S6 pore-forming regions determine its 
ion selectivity, which is quite selective for sodium ions 
(Goldin et al., 2000; Goldin, 2001). Tetrodotoxin 
(TTX) is a potent neurotoxin, which blocks action 
potentials by binding to the VGSC in cell membranes. 
The binding site of TTX is located at the pore opening 
of VGSC (Narahashi, 2008). According to the 
sensitivity to TTX, Nav1 family was described as TTX-
sensitive (TTX-S; Nav1.1-1.4, Nav1.6-1.7) and TTX-
resistant (TTX-R; Nav1.5, Nav1.8, Nav1.9). 
VGSCβs are approximately 30-40 kDa, which have 
been found that modified the channel and current 
density, kinetics and voltage-dependence of gating. To 
date, β1 to β4 of four isoforms encoded by SCN1B to 
SCN4B have been defined and they were the 
transmembrane proteins which contain a similar 
structure, consisting of one N-terminal extracellular 
immunoglobulin domain, one transmembrane segment, 
and a small intracellular domain (Brackenbury and 
Isom, 2008). 
2. VGSCαs and cancer 
With the development of patch clamp technique and 
molecular biology, the functional expressions of 
VGSCαs have been reported in cancer cells (Palmer et 
al., 2008). The group of Mustafa Djamgoz in England 
first found the sodium current in highly metastatic rat 
prostate cancer cell line Mat-Ly-Lu using patch clamp 
technique, but not in the weakly metastatic counterparts 
of AT-2 cells (Grimes et al., 1995). Over the past few 
years, researchers have described that inhibiting the 
activity of VGSCαs could significantly reduce the 
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invasion of the highly metastatic cancer cells but 
without obvious effect on weakly metastatic cancer 
cells (Roger et al., 2007; Gao et al., 2010; Diaz et al., 
2007). At present, the group of Mustafa Djamgoz in 
England and the group of Le Guennec in France have 
made the best understood about VGSCαs and cancer 
(Roger et al., 2006). In this section, we would 
summarize the functional expression of VGSC Nav1.5 
and Nav1.7 in cancer cells. 
2.1. The functional expression of Nav1.5 in cancer 
cells 
Individual VGSCαs subtypes can generate unique 
physiological signatures in different cell types and 
generate multiple expressions of individual VGSCαs 
subtypes in single cells (Diss et al., 2004). During 
recent years, increasing evidence has been accumulated 
in supporting that Nav1.5 can cause a variety of 
pathophysiological phenotypes in cancer cells 
(Schroeter et al., 2010). As we have known, Nav1.5 is 
belonging to the TTX-R isoform and encoded by the 
SCN5A gene, which is normally associated with human 
cardiac tissue and located on chromosome 3p21-24. It 
plays important roles in the excitability of atrial nd 
ventricular cardiomyocytes and in rapid impulse 
propagation (Schroeter et al., 2010). 
In 2003, the group of Le Guennec in France reported 
that VGSCαs were expressed in a highly metastatic 
breast cancer cell MDA-MB-231 but was not detected 
in the weakly metastatic MCF-7 cells (Roger et al.,
2003). Later on, the group of Mustafa Djamgoz in 
England further found that the mainly isoform 
expressed in breast cancer highly metastatic cells was 
the Nav1.5, and inhibition of Nav1.5 with TTX could 
markedly reduced the invasion of MDA-MB-231 cells 
(Fraser et al., 2005). Interestingly, our research also 
demonstrated that the abnormal expression of Nav1.5 
could be an integral component of the metastatic 
process in human ovarian cancer and inhibiting the 
activity of Nav1.5 could significant reduce the invasion 
of cancer cells (Gao et al., 2010). In addition, many 
similar discovery have also been reported a 
predominant expression of Nav1.5 in colon cancer and 
T-lymphocyte Jurkat cells (House et al., 2010; Frase  et 
al., 2004). 
Alternative splicing are sophisticated and ubiquitos 
nuclear process, they are important in normal 
development by creating protein diversity in complex 
organisms and also are natural source of cancer-causing 
errors in gene expression (Venables, 2004). Up to now, 
six Nav1.5 splice variants have been reported in Gee 
Bank (NM_000335.4; NM_001099404.1; 
NM_001099405.1; 
NM_001160160.1; NM_001160161.1; 
NM_198056.2). To date, Diss et al. and Schroeter et al. 
subsequently summarized the currently known  
functional splice variants of Nav1.5, they both 
mentioned the naturally occurring Nav1.5 splice 
variants (Diss et al., 2004; Schroeter et al., 2010). 
Among these splice variants, the D1:S3 3' splice variant 
and D1:S3 5' splice variant are the predominant, which 
can lead to multiple 5â€²- and 3â€²-noncoding regions, 
resulting in the mutations of SCN5A. Because D1:S3 5' 
splice variant differs from D1:S3 3' splice variant t 31 
nucleotides and result in 7 amino acid substitutions 
(Fraser et al., 2005), Brackenbury et al. designed th  
siRNA and a polyclonal antibody of targeting D1:S3 5' 
splice variant, which could rapidly reduce the activity 
of Nav1.5 and the invasion of MDA-MB-231 cells 
(Brackenbury et al., 2007). Further research has also
shown that the D1:S3 5' splice variant were expressed 
in cancer cells, the expression levels of different 
Nav1.5 splice variants were diversity at different stage 
of development, the D1:S3 3' splice variant gradually 
increased during the developing of organism, while 
D1:S3 5' splice variant was decreased significantly in 
the mature cells even though which is abundant at 
embryonic stage (Zimmer et al., 2002). However, 
House et al. recently found that the functional isoforms 
in colon cancer was the D1:S3 3' splice of Nav1.5 but 
not the D1:S3 5' correspondence (House et al., 2010). 
In this study, researchers presumed that the recruitment 
of Nav1.5 expression might facilitate the regulation of 
a colon cancer invasion network involving downstream 
genes which encompass the Wnt signaling way. 
Until now, the exact mechanisms by which different 
Nav1.5 splice variants functional expressed in different 
cancer cells remain unknown. Pan et al. reported that 
biochemical constitution of extracellular medium was 
critical in control of MDA-MB-231 cell motility (Pan 
and Djamgoz, 2009). Nav1.5 involving in the 
metastasis might have an indirect effect through the 
regulation of intracellular sodium homeostasis, the 
influx of Na+ could alter the release or uptake of Ca2+ 
from intracellular stores by deregulation of intracellular 
H+ concentration. Gillet et al. propose that Nav1.5 
enhance the invasiveness of MDA-MB-231 cells by 
favoring the pH-dependent activity of cysteine 
cathepsins (Gillet et al., 2009). Subsequently, Brisson 
et al. demonstrated that Nav1.5 could enhance MDA-
MB-231 cells invasiveness by increasing Na+/H+ 
exchanger type 1-dependent H+ efflux (Brisson et al., 
2011). Furthermore, the rise influx of Na+ could also 
activate protein kinase A (PKA), which could lead to 
phosphorylation of cytoskeletal components. Chioni et 
al. also founded that PKA plays an important role in 
functional expression of Nav1.5 in MDA-MB-231 cells 
by mediating activity-dependent positive feedback, and 
which enhances the metastatic of MDA-MB-231 cells 
in turn (Chioni et al., 2010). Therefore, this general 
mechanism could lead to the identification of new 
targets allowing the therapeutic prevention of 
metastases. 
 
2.2. The functional expression of Nav1.7 in cancer 
Nav1.4 was first found functionally expressed in rat 
and human prostate cancer cell lines other than skeletal 
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muscle in 1995. In this paper, the author reported that 
Nav1.4 is not only present in the highly metastatic 
MAT-LyLu and PC-3 cells, but also was detected in the 
weakly metastatic AT-2 and LNCaP cells (Diss et al., 
1998). Interestingly, Bennett et al. reported that when 
Nav1.4 was transiently expressed in non-metastatic 
LNCaP cell, its invasion was sharply increased and the 
increased invasion could be completely reversed by 
treatment with TTX (Bennett et al., 2004). However, 
further research revealed that main isoform functioally 
expressed in prostate cancer was NaV1.7 but not 
Nav1.4, and researcher concluded that the NaV1.4 
expressed in weakly metastatic cells might be at a sub-
threshold density (Roger et al., 2006; Bennett et al., 
2004). 
As we have known, the TTX-S isoform Nav1.4 is 
encoded by SCN4A gene and located on chromosome 
2, it is responsible for the generation and propagation 
of action potentials in neurons and muscle and broadly 
expressed in skeletal muscle (Jurkat-Rott et al., 2010). 
While the TTX-S isoform Nav1.7 is encoded by 
SCN9A gene and located on chromosome 2q23-24, it is 
necessary for pain sensation and broadly expressed in 
neurons (Wood et al., 2004). Recently research have 
shown that loss of function of Nav1.7 could cause a 
congenital inability to experience pain in humans, 
while gain of function of Nav1.7 could enhance the 
invasion of rat and human prostate cancer cells (Fischer 
and Waxman, 2010). 
In 2001, Diss et al. reported that the main mRNA 
isoform expressed in Mat-Ly-Lu and PC3 cells was 
NaV1.7 (Diss et al., 2001). Later on, the same research 
group reported that the functional expression of 
NaV1.7 was related with the development of prostate 
cancer, NaV1.7 might be a potential novel marker for 
human prostate cancer (Diss et al., 2005). Over the past 
few years, NaV1.7 also been reported that participated 
in the invasion in human non-small-cell lung cancer 
cells, cervical cancer cells and so on (Roger et al., 
2007; Diaz et al., 2007; Roger et al., 2006). 
However, the mechanisms responsible for the 
functional expression of NaV1.7 in metastatic cancer 
cells also remain unknown. Growth factors have been 
shown to play the important roles in regulation of 
Nav1.7 transcription in prostate cancer  
 
strongly metastatic cells (Uysal-Onganer and Djamgoz, 
2007; Ding et al., 2008). The expressions of Nav1.7 
were under auto-regulation by activity-dependent 
positive feed-back which dominated the effect of 
different growth factors and which might be made 
effect on by PKA activation. In addition, over 
expressions of Nav1.7 also induced Ca2+ influx led to 
protein kinase C α (PKCα) phosphorylation and 
glycogen synthase kinase-3β (GSK-3β) 
phosphorylation by activating activated ERK1/ERK2 
and p38 pathway (Kanai et al., 2009). 
3. VGSCβs and cancer 
Due to VGSCβs subunits are multi-functional 
molecules, they are homologous to the immunoglobulin 
superfamily of cell adhesion molecules (CAMs) and 
play important roles in regulating cellular excitablity, 
adhesion and metastatic activity in cancer (Isom, 2001). 
So far, the study of VGSCβs and cancer was mainly in 
breast cancer and prostate cancer cells. The group of 
Mustafa Djamgoz in London first found VGSCβs were 
expressed in prostate cancer cells and reducing the 
expression of β1 or disturbing its association with 
Nav1.7 could significantly reducing metastatic cell 
behaviour (Diss et al., 2008). In 2008, the same group 
further shown that the expression levels of β1 were 
significantly higher in weakly metastatic MCF-7 cells 
than strongly metastatic MDA-MB-231 cells, and 
silencing SCN1B using siRNA could increase the 
migration of MCF-7 cells, which suggested that β1
might as a novel cell adhesion molecule control the 
expression levels of Nav1.5 and cellular migration n 
breast cancer cells (Chioni et al., 2009). Therefore, it is 
inferred that VGSCβs might be involved in VGSCαs 
intracellular trafficking and functional expression by 
protein-protein interactions may, and the co-expression 
of VGSCβs and VGSCαs might increase the current 
density and the efficiency with which the mature 
channel protein was targeted to plasma membrane 
(Johnson and Bennett, 2006). 
4. Conclusions 
In conclusion, VGSC expressions were functionally up-
regulated in many cancer cells by involving in 
transcriptional, pre-translational, translational, post-
translational regulation (Shao et al., 2009). In addition, 
recent studies have reported that using of local 
anesthetics (the blockers of VGSC) during surgical 
resection of cancers was associated with a reduced risk 
of clinical cancer reoccurrence and metastasis 
(Wuethrich et al., 2010). Therefore, it should be noted 
that in the future studies that how VGSC activity 
participate in the progress of cancer, and VGSC 
functional expression in cancer cells might represent a 
novel mechanism for potentiating cellular metastasi 
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